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E-mail address: marahiel@staff.uni-marburg.de (MPeptide natural products continue to play an important role in modern medicine as last-resort
treatments of many life-threatening diseases, as they display many interesting biological activities
ranging from antibiotic to antineoplastic. A large fraction of these microbial natural products is
assembled by ribosome-independent mechanisms. Progress in sequencing technology and the
mechanistic understanding of secondary metabolite pathways has led to the discovery of many for-
merly cryptic natural products and a molecular understanding of their assembly. Those advances
enable us to apply protein and metabolic engineering approaches towards the manipulation of
biosynthetic pathways. In this review we discuss the application potential of both templated and
non-templated pathways as well as chemoenzymatic strategies for the structural diversiﬁcation
and tailoring of peptide natural products.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The rapid progress of whole genome sequencing of microorgan-
isms and the parallel development of ever more sophisticated bio-
informatic tools have revealed that up to 10% of entire bacterial
and fungal genomes can be dedicated to secondary metabolite
assembly [1–5]. In these microorganisms the genes encoding sec-
ondary metabolite pathways are usually grouped in clusters con-
taining pathway-speciﬁc regulators and transport systems. They
represent a largely untapped library of biologically active mole-
cules and putatively new scaffolds that has been speciﬁcally pre-
selected by evolution for stability and bioactivity. Genome-mining
approaches as well as microbial metagenomics represent two
promising strategies to uncover this vast biosynthetic potential
with various sources suggesting that less than 1% of microbial
diversity has been investigated so far [6]. Many of those pathways
are responsible for the production of peptidic natural products
whose assembly does not rely upon the ribosomal machinery [7–
9]. Those ribosome-independent peptides constitute a diverse class
of secondary metabolites showing a wide variety of impressive
biological activities. Notable examples currently in clinical use
are the glycopeptide antibiotic vancomycin [10], the lipopetidecal Societies. Published by Elsevier
hemistry, Philipps-University
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.A. Marahiel).antibiotic daptomycin [11] and the immunosuppressant FK506
(Fig. 1) [12,13]. They all contain peptide bonds formed by non-
ribosomal peptide synthetases (NRPSs), large modular enzymes
working in an assembly-line fashion, where each module is
responsible for the incorporation of a single monomer [14,15]. In
the biosynthesis of all non-ribosomal peptides fully or partially
assembled by NRPSs the enzymatic machinery itself functions as
a template for the synthesized peptide product. For this reason
those pathways are referred to as templated pathways in contrast
to non-templated pathways, where no deduction of the resulting
monomer arrangement in the product is possible using solely the
responsible biosynthetic catalysts. In NRPS-systems monomer
selection and activation is achieved by adenylation domains (A)
whose resulting adenylated products are subsequently attacked
by the nucleophilic thiol group of a 40-phosphopentethein cofactor
covalently linked to a dedicated carrier domain (T), preserving the
energy initially provided through ATP hydrolysis in a reactive thi-
oester bond. Subsequent peptide bond formation between two
adjacent T-bound aminoacyl or peptidyl intermediates is catalyzed
through condensation domains (C) which at the same time per-
form the downstream translocation of the respective intermediates
(Fig. 2A) [14,15]. Besides NRPS-pathways and hybrids thereof at
least four different non-templated pathways exist for the genera-
tion of peptide bond containing secondary metabolites (Fig. 2B).
One of those enzyme classes capable of catalyzing peptide bond
formation is the acyl-AMP ligase family that activates a substrateB.V. Open access under CC BY-NC-ND license.
Fig. 1. Peptide natural products assembled independently of the ribosome. Shown are examples for templated pathways (NRPS, NRPS/PKS), non-templated pathways (CDPS,
ATP-grasp/acyl-AMP-ligases) and hybrids thereof (NRPS/tRNA-AT). NRPS: non-ribosomal peptide synthetase, PKS: polyketide synthase, tRNA-AT: tRNA-aminoacyltransferase,
CDPS: cyclodipeptide synthase.
A B
Fig. 2. Monomer activation and peptide bond formation of enzymes involved in secondary metabolite biosynthesis. (A) Stepwise mechanism of templated NRPS-pathways.
(B) Stepwise mechanisms of four non-templated pathways. (I) Acyl-AMP-ligases, (II) ATP-grasp-ligases, (III) tRNA-dependent aminoacyltransferases, (IV) tRNA-dependent
cyclodipeptide synthases.
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similar to the activation reaction found in NRPS-systems, and addi-
tionally catalyzes the subsequent formation of a peptide bond be-
tween the activated acyl-AMP intermediate and an amino group of
a free cosubstrate (Fig. 2B: I) [16]. One recently characterized pep-
tide partially produced by an acyl-AMP ligase (DdaG) is the antibi-
otic dapdiamide [17–19]. Interestingly a second distinct class of
peptide bond forming enzymes is involved in the biosynthesis of
this non-templated tripeptide, namely an ATP-grasp ligase (DdaF).
In contrast to the activation strategies mentioned before, ATP-
grasp ligases transform a substrate carboxylate into a high energy
mixed anhydride intermediate through the attachment of a phos-
phate group, resulting in the generation of ADP as the ATP-hydro-
lysis product (Fig. 2B: II) [20]. As described for the acyl-AMP
ligases, a free substrate subsequently attacks the activated carbox-
ylate via an amino group thus establishing the new peptide link-
age. Two distinct recently identiﬁed enzyme families are also
capable of catalyzing the formation of peptide bonds in secondary
metabolites employing a different monomer activation strategy.
The family of Fem-like ligases, as exempliﬁed by the aminoacyl-
transferase PacB involved in the biosynthesis of the peptidyl nucle-
oside antibiotic pacidamycin (Fig. 2B: III) [21–24] and the so called
cyclodipeptide synthases (CDPSs, Fig. 2B: IV) [25,26], use
tRNA-bound amino acids, generated through the action of the cor-
responding aminoacyl-tRNA synthetases (aaRSs), directly as sub-
strates for the subsequent formation of peptide bonds. By
hijacking aminoacyl-tRNAs as already activated substrates no ATP-
ase activity is required for enzymes of those families, who repre-
sent a direct connection between primary and secondary
metabolic pathways. In contrast to PacB, which uses one amino-
acyl-tRNA and a free amino group containing molecule as sub-
strates [21], CDPSs use two tRNA-bound amino acids to establish
two new peptide bonds resulting in the generation of a diketopi-
perazine (DKP) moiety [27,28], as could be shown for the CDP anti-
biotic albonoursin [29].
Efforts towards the continued discovery of new bioactive pep-
tidic natural products and studies aiming to improve our under-
standing of their biosynthetic pathways will not only be crucial
in the general attempt to ﬁnd and develop new pharmacologically
valuable compounds and in addressing fundamental aspects of bio-
logical systems, but will most likely be our best chance to ﬁght the
major medical problem of antibiotic resistance. Historically the
major source of clinically used antibacterial agents has been sec-
ondary metabolites of bacteria and fungi or derivatives thereof,
with 69% of clinically introduced compounds between 1981 and
2006 originating from natural sources [30]. Looking at the lack of
marketed drugs or late phase clinical candidates resulting from
synthetic combinatorial chemistry [31], it is likely that bioactive
natural products will continue to be the primary source of new
antibacterial compounds, despite decreasing investments of the
pharmaceutical industry in natural product discovery programs.
The fact that many peptide secondary metabolites are structurally
complex, containing multiple chiral centers and labile functional-
ities makes them difﬁcult to synthesize chemically. Therefore ap-
proaches employing biosynthetic and fermentative strategies are
important tools for the production and development of function-
ally valuable compounds [32].
It is in this light that synthetic biology, usually deﬁned as the de
novo design of new or the redesign of existing biological systems,
ranging from single enzymes (protein engineering) to whole bio-
synthetic pathways (metabolic engineering), offers new ap-
proaches and methodologies that may help to tackle this urgent
problem [33–36]. Microbial peptide natural product pathways in
general and NRPS-pathways in particular possess several levels of
intrinsic modularity making them especially amenable to engi-
neering approaches for the modiﬁcation of existing or the combi-natorial generation of entirely new bioactive compounds referred
to as unnatural natural products.
In this review an overview of recent developments in the ﬁeld of
combinatorial biosynthesis and engineering of non-ribosomal pep-
tide biosynthetic pathways is given. First we outline approaches
that seek to generate structural diversity through manipulation of
the peptide backbone itself, focusing not only on NRPS-systems
but also taking peptide bond forming non-templated secondary
metabolite pathways into account. Afterwards we investigate the
possibilities presented by the use of dedicated tailoring enzymes
for themodiﬁcation of peptide scaffolds as well as chemoenzymatic
synthesis strategies. Lastly challenges in engineering peptide natu-
ral product biosynthesis as well as future directions are discussed,
where we outline a possible strategy how the synthetic biology
concept of standardized and compatible parts can be of use in the
de novo design and assembly of new bioactive peptides.2. Generating structural diversity through manipulation of the
peptide backbone
There are two general ways to create structural diversity in pep-
tide natural products. Firstly by manipulating the peptide back-
bone itself and secondly by decoration of the already assembled
peptide scaffold using dedicated tailoring enzymes to introduce
new chemical functionalities. In nature both approaches are uti-
lized in the evolution of new functional biosynthetic gene clusters
by mutation of single genes as well as insertions, deletions and
duplications of functional modules at different organizational lev-
els often leading to the merging of formerly separate biosynthetic
pathways, as impressively exempliﬁed by the antifungal agent leu-
pyrrin which joins four different metabolic pathways to generate
one single product [37,38]. Both mentioned strategies can result
in drastic changes in physicochemical properties and thus biologi-
cal activities through structural rigidiﬁcation and alteration of
hydrophobicity or overall charge of the modiﬁed peptide [39].
Peptide backbone structure can be modulated by the kind, num-
ber and connectivity of the constitutive monomeric units. A key
concept for the structural diversiﬁcation of ribosome-independent
peptide structures is taking advantage of the inherent modularity
present in their respective biosynthetic pathways [38]. All micro-
bial secondary metabolite pathways display modularity at differ-
ent levels of organization. Those modules can be used as building
blocks that can be recombined in new ways in the engineering of
secondary metabolite biosynthesis. The highest level of organiza-
tion is the clustering of all needed functionalities of a particular
pathway into biosynthetic gene clusters, which can be further sub-
divided into multiple functional operons, each being responsible
for the biosynthesis of a certain part of the produced metabolite
[15,40]. Operons themselves are modular, consisting of distinct
genes that can introduce particular new functionalities into a nat-
ural product, as exempliﬁed by many tailoring enzymes found in
various natural product pathways. Templated pathways display
an additional level of modular organization compared with non-
templated biosynthetic strategies. On the protein level they consist
of functional modules, which are themselves composed of individ-
ual catalytic domains, each responsible for a certain task in the bio-
synthesis and maturation of the assembled peptidic natural
product.
2.1. Templated pathways
2.1.1. Altering monomer identity
Concerning templated pathways different approaches for the
structural diversiﬁcation of peptide products have been explored
that concentrate on altering the identities of the incorporated
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tation of a producing organism with unnatural building blocks and
not on the engineering of the biosynthetic machinery itself are the
so called precursor-directed biosynthesis [41] and mutasynthesis
[42,43] approaches. Precursor-directed biosynthesis utilizes chem-
ically synthesized precursor analogs for the in vivo incorporation
into a natural product using only the endogenous biosynthetic
machinery of the producer and relying on the inherent substrate
promiscuity of the responsible biocatalysts as well as on the suc-
cessful uptake of the respective analogs. Additionally putative toxic
effects of the unnatural precursors have to be considered, limiting
the accessible concentration range and thus the percentage of
incorporation. The applicability of this approach has been shown
with the generation of many modiﬁed enniatins [44–46] and
beauvericins [47,48], fungal secondary metabolites produced by
NRPSs possessing a variety of promising biological activities. Muta-
synthesis represents an extension of the precursor-directed bio-
synthetic strategy where mutants of the natural producer are
generated that are impaired in the biosynthesis or utilization of
endogenous precursors, thus leading to an enhanced incorporation
of modiﬁed unnatural building blocks. Mutasynthesis has been
shown to be a useful tool for the generation of structural diversity
in many different natural product classes, including peptides pro-
duced by NRPSs [49–51]. A different approach for the generation
of diversity at the monomer level is the engineering of the biosyn-
thetic machinery itself so that precise changes in monomer compo-
sition can be introduced into a peptide natural product (Fig. 3).Fig. 3. Strategies for the structural diversiﬁcation of peptide natural products at the mono
NRPS-pathways. The generation of structural diversity can be accomplished by changinInitial proof-of-principle studies were carried out by engineering
the biosynthetic machinery of the lipopeptide antibiotic surfactin
through substitution of the terminal leucine-incorporating A–T
fragment with different bacterial and fungal A–T-didomains
employing a homologous recombination approach that resulted
in biologically active surfactin variants [52]. Subsequent engineer-
ing attempts focused on the substitution of complete functional
modules or subunits consisting of the canonical C-, A- and T-do-
mains required for peptide elongation [53–55]. Recently novel
daptomycin-derived lipopetides as well as derivatives of the re-
lated lipopetide A54145 could be generated by this so called mod-
ule swapping approach using a k-Red-mediated recombination
strategy for the construction of hybrid assembly lines yielding
engineered products with improved antibacterial properties com-
pared to the wild type compounds [56,57]. Beside attempts in
whole module substitution, a second engineering strategy was ex-
plored for changing the identity of incorporated monomers where
single A-domains, responsible for the initial selection of a certain
building block, were exchanged [58,59]. After discovery of the
speciﬁcity-conferring code, a set of amino acid residues lining the
substrate binding pocket in A-domains, through sequence align-
ments and structural studies a new possibility for altering mono-
mer identity presented itself by rationally redesigning this code
[59–61]. Unfortunately this proofed to be not a straightforward
task and only a few conservative speciﬁcity changes have been re-
ported so far [62,63]. A successful alteration of substrate speciﬁcity
could also be achieved using a computational redesign strategy notmer level using engineering approaches of the biosynthetic machinery in templated
g either monomer identity, number or connectivity.
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tional design approaches for the reprogramming of A-domain spec-
iﬁcity directed evolution experiments try to mimic natural
evolution of substrate diversity on a vastly shorter time scale by
creating randomized libraries coupled with subsequent artiﬁcial
selection based on the desired outcome [66]. Using directed evolu-
tion A-domain speciﬁcity of the starting module TycA from the
tyrocidine biosynthetic system could be changed from phenylala-
nine towards alanine by targeting only the residues of the speciﬁc-
ity-conferring code. The authors demonstrated that by using a
rather promiscuous activity as a starting point and a small library
size it is possible to generate A-domains with altered speciﬁcity
and substantial rate enhancements after only two rounds of satu-
ration mutagenesis [67,68].
2.1.2. Altering the number of monomers
Structural diversity with regard to the peptide backbone cannot
only be achieved by monomer substitution, but also by a reduction
or increase in the number of constitutive building blocks. Studies
focusing on this approach either employ a module deletion or
insertion strategy (Fig. 3). By in-frame deletion of an entire module
in the surfactin biosynthetic system it was possible to generate the
expected cyclic hexapeptide variant instead of the wild type hep-
tapetide showing that it is possible to exploit NRPS modularity to
alter the number of monomers incorporated into a peptide product
[69]. A different strategy for the generation of shortened NRPS
products was discovered by Wenzel et al. in the myxochromide
system through the ﬁnding that point mutations in a certain T-do-
main render its respective module completely inactive, leading not
to abolished peptide production as expected but to the generation
of a variant missing the building block normally incorporated by
this module [70]. Regarding the introduction of extra monomers,
insertion of an additional building block by module extension
was achieved for the vancomycin-like glycopeptide antibiotic bal-
himycin through insertion of an entire D-hydroxyphenylglycine
incorporating module resulting in the generation of the expected
elongated octapeptide product [71].
Despite promising initial results in combinatorial biosynthesis
using templated pathways as starting points for engineering ven-
tures and its obvious application potential, there are several asso-
ciated problems and technical bottlenecks that have impeded a
more rapid development. Basically all studies discussed above
using module or domain swapping approaches or A-domain spec-
iﬁcity alteration strategies suffer from the fact that the resulting
engineered assembly lines are functionally impaired resulting in
low yields of modiﬁed peptide products compared to wild type
levels. One major problem regarding the practicality of NRPS sys-
tems for simple cut-and-paste protein engineering approaches,
inherent in assembly line enzymology, is the fact that A-domains
are not the only speciﬁcity determinants present in NRPS sys-
tems. The condensation catalysts (C-domains), used by NRPSs to
carry out the critical peptide bond forming steps, were shown
to possess a certain degree of substrate speciﬁcity themselves,
especially at their acceptor sites, depending on monomer identity
and chain-length and consequently represent a second speciﬁcity-
conferring system within NRPS systems [72,73]. Thus engineering
assembly lines de novo using functional modules of different ori-
gin could result in the production of intermediates that are not
efﬁcient substrates for subsequent biosynthetic steps, ultimately
leading to the premature hydrolytic release of intermediates
and hence preventing the production of the desired peptide prod-
uct [63]. A second challenge was the identiﬁcation of proper
recombination sites within NRPS assembly lines so that the intro-
duction or excision of certain domains or modules would not re-
sult in the inactivation of neighboring domains by disturbed
protein–protein interactions or in the disruption of overall en-zyme integrity. This problem could be partially addressed by
the identiﬁcation of conserved linker regions between functional
domains using information gained from sequence analysis as well
as biochemical and structural studies [61,74,75]. Additionally the
high-resolution crystal structure of a complete NRPS termination
module showed that the C- and A-domain form a strongly inter-
acting workbench-like complex indicating that they could consti-
tute a speciﬁcity-conferring unit which should be taken into
consideration in future engineering attempts [76]. Combining
the knowledge about linker regions with a directed evolution ap-
proach using a naturally promiscuous system to circumvent pos-
sible problems resulting from mismatched C-domain speciﬁcity
Fischbach et al. were able to optimize the production capability
of a chimeric andrimid-cytotrienin assembly line by an order of
magnitude compared to the non-evolved synthetase [77]. By
employing an error-prone PCR mutagenesis approach they were
able to optimize protein-protein interactions of the newly intro-
duced A- and its downstream T-domain and thus were able to
rescue the overall activity of the biosynthetic system. In a re-
cently published study Evans et al. used directed evolution to
change the substrate speciﬁcity of AdmK via saturation mutagen-
esis targeting only the most highly variable A-domain active site
residues, resulting in the generation of four andrimid variants
containing amino acid substitutions at the expected site [78].
Interestingly the authors did not use a bioassay-guided screening
strategy, reasoning that they would be incapable of identifying
which precise andrimid derivatives were produced, but instead
established a structure-based assay that would provide a direct
readout of not just the altered AdmK activity, but also the ﬁnal
assembly line output. This use of a high-throughput multiplexed
LC–MS/MS screening approach opens the intriguing possibility
to directly connect the overall impact of mutagenesis to the pro-
duction of new derivatives. Another area were concentrated ef-
forts have resulted in new insights useful for combinatorial
biosynthesis of NRPS products is concerned with the in trans
interaction of partner modules in NRPS assembly lines. Communi-
cation-mediating domains (COM-domains) were shown to control
the interactions of distinct NRPS subunits and are as such respon-
sible for the order in which the respective NRPS modules are used
and in extension determine the resulting monomer sequence
found in the mature peptide natural product [79,80]. Swapping
of COM domains has been used in the production of surfactin
variants in Bacillus subtilis with different peptide chain lengths,
showing that the usage of distinct modules with complementary
COM-domains is a powerful tool for the rational design of a de-
sired amino acid sequence [81]. In a recent study the application
of communication-mediating domains was extended to a eukary-
otic host using Saccharomyces cerevisiae for the production of a D-
Phe-L-Leu dipeptide by TycA and SrfAC equipped with compatible
COM-domains [82]. This shows that combinatorial biosynthesis
using discrete NRPS modules, where the resulting product se-
quence is determined by the use of compatible COM-domains,
can also be applied in a eukaryotic host, which may be advanta-
geous as a production platform if modules of eukaryotic origin are
employed [83].
2.1.3. Altering monomer connectivity
The major strategy by which nature modulates the connectivity
of monomeric units in NRPS-derived peptide natural products is
macrocyclization [84]. The potent bioactivity of many peptides re-
lies on the introduction of an intramolecular covalent linkage be-
tween distant parts of a molecular scaffold resulting in a reduced
number of possible conformations and thus entropically favoring
the bioactive conformation required for a speciﬁc interaction with
a biological target. Additionally the formation of closed macrocy-
clic structures confers protection against proteolytic degradation
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chemical stability [39]. Different types of macrocyclization strate-
gies are used to generate structural diversity in NRPS products
that differ in two major ways, namely the nature of the newly
established chemical bond and the type of cyclic structure formed.
In principle macrocyclization can result in the formation of truly
closed structures via head-to-tail cyclization as exempliﬁed by
the peptide antibiotic tyrocidine A [85,86] or in branched-cyclic
structures if one of the reacting functionalities is not located at
the C- or N-terminus of the peptide as found in the lipopeptide
antibiotic daptomycin [11,87]. The bond that establishes the cova-
lent linkage is usually an amide or ester bond resulting in macro-
lactam (tyrocidine A) or macrolacton (daptomycin) formation,
respectively. Diverging from those common macrocyclization
strategies are cases where cyclic structures are formed through
cyclooligomerizations of identical building blocks. For example,
the siderophore enterobactin is biosynthesized via a trimerization
of 2,3-dihydroxybenzoyl-seryl dipeptide units to generate a 12-
membered macrocyclic ring containing three ester bonds [88].
Not only amide and ester linkages are employed in the formation
of cyclic structures, e.g. the antitumor agent thiocoraline is assem-
bled via a cyclooligomerization strategy using two unusual thioes-
ter bonds to establish a macrocyclic ring. Interestingly, a second
covalent linkage is introduced into the thicoraline molecule
through disulﬁde bond formation resulting in a bicyclic structure
of the mature thiodepsipeptide [89,90]. Another unusual macrocy-
cle forming bond can be found in the cytotoxin nostocyclopeptide
A2, where a stable imino bond links both ends of the linear hepta-
peptide [91].
Macrocyclizations in NRPS-systems are carried out by the last
domain of an assembly line, leading to the release of the mature
product and to the regeneration of the multienzyme complex for
the next catalytic cycle. In most cases thioesterase domains (TE-
domains) function as the termination catalysts responsible for
product release [84]. They either catalyze a hydrolytic cleavage
leading to the formation of a linear peptide (e.g. the vancomycin-
type antibiotics) [92] or an intramolecular nucleophilic attack that
results in a macrocyclic structure. Alternatively so called iterative
TE-domains [93] are capable to carry out cyclooligomerization
reactions where the oligomerized intermediate is ﬁrst assembled
while tethered to the thioesterase domain and subsequently serves
as a substrate for macrocyclization (e.g. enterobactin). In addition
to TE-catalyzed chain termination, reductive release catalyzed by
NAD(P)H-dependent C-terminal reductase domains (R-domains)
can also be found in NRPS-systems. They either form reactive alde-
hydes followed by the attack of a suitable nucleophile leading to
macrocyclization as exempliﬁed in the biosynthesis of nostocyclo-
peptide A2 [94] or are involved in the formation of further reduced
compounds like primary alcohols and amines (e.g. found in linear
gramicidin) [95]. A third possibility for chain termination and
macrocyclization could be realized by C-terminal condensation do-
mains putatively capable of catalyzing the formation of macrocy-
clic structures as proposed for the biosyntheses of rapamycin and
FK506 [13]. Interestingly many fungal NRPS assembly lines possess
a C-terminal C-domain indicating that in those systems condensa-
tion domains represent the main chain termination strategy
contrary to prokaryotic systems where TE-domains are most com-
monly used [96,97].
With the de novo engineering of bioactive ribosome-indepen-
dent peptides in mind structural diversiﬁcation could be achieved
by substituting the chain termination catalysts in NRPS pathways
resulting in the production of desired cyclic or branched-cyclic
structures or further reduced functionalities. This possibility intro-
duces an additional strategy with which tailored peptide natural
products could be rationally engineered focusing on the alteration
of building block connectivity (Fig. 3).2.2. Non-templated pathways
In secondary metabolism other classes of peptide bond forming
catalysts exist that do not work in an assembly line fashion but
represent discrete enzymes that condense soluble substrates
resulting in a new peptide linkage. Those enzymes can be differen-
tiated by their mode of monomer activation and use of different
substrates (Fig. 2B). In the context of combinatorial biosynthesis
one can envision a scenario where peptide bond forming enzymes
like acyl-AMP-ligases and ATP-grasp-ligases could be used to add
certain building blocks to speciﬁc sites in an already assembled
amino acid chain, based on their inherent or engineered substrate
speciﬁcities. The use of peptide bond forming catalysts in a tailor-
ing enzyme fashion after assembly of the core peptide scaffold
would increase the potential for structural diversity in peptide nat-
ural products enormously and would represent a next step in the
rational design of bioactive peptidic compounds (Fig. 4).
Two additional classes of peptide bond forming enzymes share
an unusual feature by directly using already activated amino acids
in the form of aa-tRNAs to establish peptide linkages (Fig. 2B).
Depending on the speciﬁcity determining factors in those reac-
tions, structural diversity could be generated by using tRNAs
loaded with unnatural amino acids as substrate or by modulating
speciﬁcity via directed evolution approaches. In the case of cyclod-
ipeptide synthases this would lead to side chain modiﬁed cyclodi-
peptides putatively expanding the scope of the privileged
diketopiperazine scaffold for the generation of new biologically ac-
tive molecules [98]. Initial studies of CDPSs showed that some cyc-
lodipeptide synthases possess a rather relaxed substrate speciﬁcity
indicating that they might be amenable to direct modiﬁcation ap-
proaches by using tRNAs loaded with unnatural amino acids
(Fig. 4) [25,26,28]. An especially intriguing thought is the possibil-
ity of introducing building blocks carrying azido or alkyne func-
tionalities for further modiﬁcation by click-chemistry. This would
result in the possibility of directly adding a plethora of desired
functional building blocks to the DKP scaffold using the well-estab-
lished Huisgen cycloaddition [99]. The recently discovered class of
tRNA-dependent aminoacyltransferases as exempliﬁed by PacB
could, after elucidation of their substrate speciﬁcities, be used in
a similar way to introduce unusual building blocks into an already
assembled peptide scaffold (Fig. 4) [24].3. Generating structural diversity through the action of
dedicated tailoring enzymes
In principle tailoring enzymes encoded in a biosynthetic gene
cluster can act at three different stages in the natural product
assembly process. Firstly on a soluble monomeric substrate result-
ing in the generation of modiﬁed building blocks that differ from
those used in primary metabolism. Secondly on sequestered mono-
mers covalently tethered to assembly line enzymes of templated
pathways and thirdly on the already assembled core scaffold of a
natural product representing a late biosynthetic step in natural
product maturation [100]. A second distinction can be made with
regard to modifying enzymes found in templated pathways.
NRPS-systems can contain optional in cis acting modifying do-
mains imbedded in the assembly line machinery as well as in trans
acting tailoring enzymes that can act at all three biosynthetic
stages mentioned above. The most common modifying domains
found in NRPS-systems are epimerization- (E-), heterocyclization-
(Cy-), oxidation- (Ox-) and N-methylation-domains (MT-domains)
[15]. It could be argued that E- and Cy-domains directly modulate
peptide backbone structure and thus should have been discussed
in the previous section, but because they do not introduce new
peptide bonds or alter building block connectivity, which have
Fig. 4. Application of enzymes originating from non-templated pathways to generate structural diversity. Wild-type or engineered acyl-AMP-ligases, ATP-grasp-ligases and
tRNA-dependent aminoacyltransferases can be used to attach additional building blocks to a natural or modiﬁed peptide generating further structural variants. Depending on
their natural or engineered substrate speciﬁcities cyclodipeptide synthases can be used to form modiﬁed diketopiperazines by providing tRNA-substrates loaded with
unnatural amino acids.
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cussed here. E-domains are capable of changing a-C stereoconﬁg-
uration resulting in an overall change of peptide backbone
conformation [101], while Cy-domains can introduce heterocyclic
structures into a peptide chain by catalyzing the nucleophilic at-
tack of a serine, threonine or cysteine hydroxyl or thiol group on
the upstream carbonyl followed by dehydration of the adduct
resulting in oxazoline or thiazoline formation [102]. In conjunction
with in cis acting Ox-domains [103] or in trans acting reductases
[104] those heterocyclic structures can be further oxidized to oxaz-
oles and thiazoles or reduced to yield oxazolidines and thiazoli-
dines. The presence of MT-domains in a particular NRPS-module
results in the SAM-dependent N-methylation of the respective
building block modulating the overall conformation and hydro-
phobicity of the resulting peptide [105].
With regard to combinatorial biosynthesis domain swapping
could be extended from A-domains to in cis modifying domains
to alter a certain building block in a rational fashion. The feasibility
of such domain swapping approaches has been demonstrated by
swapping the E-domain of PchE from the pyochelin system with
the Ox-domain of MtaD involved in myxothiazol biosynthesis
resulting in the generation of advanced intermediates containing
the expected heterocyclized building block [106].
In nature the majority of structural diversity observed for a gi-
ven family of molecules, partly sharing a biosynthetic pathway, re-
sults from variations in genes coding for distinct tailoring enzymes.
Among the many different transformations catalyzed by tailoring
enzymes are glycosylations, acylations, oxidations, reductions,
methylations, and halogenations. With regard to pathway manipu-
lation introducing a change in the later stages of a biosynthetic
pathway can avoid problems resulting from narrow substrate spec-
iﬁcities of other required pathway enzymes. Therefore tailoring en-
zymes that mainly act in the late stages of a certain pathway, often
representing the last step of product maturation, are interesting
targets for the generation of structural diversity. With respect to
in trans acting tailoring enzymes a distinction between their appli-
cation in vivo and their use in a chemoenzymatic fashion in vitro
can be made. Regarding the in vivo approach the simplest strategy
to introduce structural diversity into a secondary metabolite is to
disrupt a particular gene coding for a downstream acting tailoring
enzyme as could be shown for different natural product classes
[107–109]. The applicability of this strategy toward peptide natu-
ral products could be shown through the inactivation of the glu-
tamic acid 3-methyltransferase gene coupled with an already
mentioned module swapping approach (Section 2.1.1) in the dap-
tomycin system yielding new lipopeptide-variants containing the
expected non-methylated building block [56]. Beside the inactiva-tion of tailoring enzymes resulting in the loss of certain functional
groups it is also possible to add new in trans acting modifying en-
zymes to an existing pathway to introduce entirely new function-
alities to a natural product scaffold. Using this approach Li et al.
were able to generate new derivatives of the aminocoumarins
novobiocin and clorobiocin by replacing the methyltransferase
gene in the novobiocin gene cluster with the chlorinase gene orig-
inally from the clorobiocin cluster and vice versa. This resulted in
the introduction of a methyl or chloro group at the C-8 position
of the aminocoumarin scaffold usually not found in the respective
molecule [110]. One of the most prominent tailoring reactions
found in many peptidic secondary metabolites is glycosylation. Su-
gar residues are key determinants of bioactivity in many glycopep-
tides and additionally serve as scaffolds for further modiﬁcation.
The feasibility of using glycosyltransferases for the generation of
new glycopeptide variants has been demonstrated by the in vivo
production of new A47934-derivatives using exogenous glycosyl-
transferases from the vancomycin and chloroeremomycin systems
[111]. Recently much effort has been dedicated to engineering gly-
cosyltransferases towards broader substrate speciﬁcities for both
their sugar and aglycon substrates. In this regard both site-directed
mutagenesis and directed evolution approaches have been em-
ployed successfully [112]. Examples of successful in vitro glycodi-
versiﬁcation include the generation of methymycin, vancomycin
and calicheamicin derivatives [113]. One of the major drawbacks
of in vitro glycosylation strategies, namely that a library of rare
and unusual nucleotide sugar donors is required, has recently been
solved by employing promiscuous nucleotide-donor sugar biosyn-
thetic enzymes and by taking advantage of the reversibility of cer-
tain glycosyltransferase reactions [114,115].
This in vitro application of glycosyltransferases in a chemoenzy-
matic fashion has some inherent advantages compared to in vivo
approaches. For one the diversiﬁcation reactions take place under
precisely controlled conditions preventing undesired side reactions
and thus improving the overall reaction efﬁciency. Secondly issues
resulting from product toxicity effecting the producing strain are
irrelevant and thirdly the diversiﬁcation potential is not limited
to those aglycone acceptors and sugar donors that can be biosyn-
thesized by or fed to the production host. The same is true for
the use of other tailoring enzyme classes for the in vitro modiﬁca-
tion of natural product scaffolds. The ﬁeld of chemoenzymatic syn-
thesis seems especially promising for the generation of analogue
libraries of candidate drugs for subsequent use in structure–activ-
ity relationship studies aimed to modulate the desired property of
a lead compound. Beside glycosylation two other modiﬁcations
have been the subject of many chemoenzymatic studies, namely
macrocyclization and oxidation of unactivated C–H bonds. TE-do-
Fig. 5. Outline of a possible workﬂow showing how the de novo construction of unnatural natural products could be realized based on templated NRPS-pathways. Starting
with the construction of hybrid synthetases via protein engineering, the resulting chimeric enzymes would be subjected to directed evolution using only two compatible
modules in the beginning. After functional optimization based on the desired structural readout an additional module would be added and directed evolution would again be
used to mutate only the new module but using the desired tripeptide for the screening. Finally a library of compatible modules can be assembled in an optimized production
host resulting in the production of the desired de novo constructed product.
2072 T.W. Giessen, M.A. Marahiel / FEBS Letters 586 (2012) 2065–2075mains, discussed in the previous section in the context of modulat-
ing peptide backbone connectivity, have been shown to be proliﬁc
macrocyclization catalysts when excised from their native assem-
bly line and used in a chemoenzymatic fashion. The fact that many
natural products, including peptidic secondary metabolites,
contain macrocyclic rings that equal or exceed eight atoms makes
them challenging targets for synthetic chemists. In many cases
those problems can be circumvented by the use of excised TE-do-
mains in either solution-phase or solid-phase chemoenzymatic
approaches as has been shown for tyrocidine and cryptophycin,
respectively [116,117]. One of the major challenges in modern or-
ganic synthesis is the targeted modiﬁcation of unactivated C–H
bonds and alkenes. To tackle this problem, tailoring enzymes found
in natural product pathways, especially heme-containing P450 en-
zymes and non-heme iron oxygenases, represent an interesting
alternative to modern transition-metal based methodologies. The
capability of those enzymes of effecting many difﬁcult oxidative
transformations on natural product scaffolds under physiologicalconditions makes them attractive as catalysts in chemoenzymatic
syntheses. Recently the applicability of P450 enzymes in chemoen-
zymatic synthesis was demonstrated in the cryptophycin system
by the stereoselective in vitro synthesis of different b-epoxy crypt-
ophycins by the P450 epoxidase CrpE [118]. Another recent study
showed that through the use of the engineered non-heme iron oxy-
genase AsnO it was possible to stereospeciﬁcally generate the
medically important molecule L-threo-hydroxyaspartic acid
in vitro [119]. The examples discussed above clearly demonstrate
the application potential of using tailoring enzymes, originating
from natural product pathways, for either the precise in vitro tai-
loring or diversiﬁcation of various natural product scaffolds.
4. Challenges and perspective
The examples mentioned and discussed in the previous sec-
tions undoubtedly show the huge potential of synthetic biology
for the production of rationally engineered bioactive peptidic nat-
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Despite many success stories in protein and metabolic engineer-
ing there are up till now relatively few examples of compounds
relying on engineering approaches actually produced at an indus-
trial scale, the most prominent example being the antimalarial
drug precursor artemisinic acid currently produced using an engi-
neered yeast strain [120]. A major challenge in the protein engi-
neering of templated NRPS-pathways using domain or module
swapping approaches has been the fact that most of the resulting
chimeric synthetases were functionally impaired yielding only
small amounts of the desired product. This is thought to result
from the disruption of protein-protein interactions needed for
efﬁcient processing of intermediates as well as from the inherent
problem of non-matching substrate speciﬁcities of downstream
C-domains. This problem could be circumvented by the applica-
tion of directed evolution strategies aiming to improve overall
synthetase performance using MS-based screening systems as
discussed above. This innovative screening approach is indepen-
dent of bioactivity and is thus uniquely positioned to deliver a di-
rect structure-based readout in directed evolution experiments.
Another challenge is the assembly of functional engineered bio-
synthetic pathways in an appropriate host. The production of nat-
ural products in their native hosts is usually hampered by low
yields and the fact that many proliﬁc producers of natural prod-
ucts are slow growing and genetically intractable. Thus it is desir-
able and in the case of de novo designed pathways or pathways
originating from uncultivable organisms even necessary to estab-
lish optimized heterologous production hosts. Many strategies
can be employed to improve metabolic ﬂux toward production
of a desired compound ranging from the increase in precursor
supply, overexpression of certain bottle neck enzymes and alter-
ation of gene expression to the reduction of ﬂux toward un-
wanted by-products or competing pathways [121]. Challenges
involved in the introduction of the often very large biosynthetic
genes found in templated pathways into a heterologous host
using expression vectors can be tackled by introducing them into
the chromosomal DNA using the recently successfully applied k-
Red recombination approach [56,57]. A different interesting sys-
tem developed by Watanabe et al. uses a strategy with which
the complete echinomycin biosynthetic gene cluster was assem-
bled on three separate plasmids adding individual promoters
and terminators to each gene [122]. The use of multi-monocis-
tronic cassettes eliminates the need to control gene orientation,
improves the efﬁciency of plasmid construction and results in
comparable levels of protein production leading to improved
product titers.
Finally a short perspective shall be given on how future de novo
engineering using templated pathways could be realized. After ini-
tial protein engineering employing domain swapping approaches
to endow a given module with the desired biosynthetic capability
as well as the addition of compatible sets of COM-domains to con-
trol the resulting monomer sequence, the resulting engineered
modules will be subjected to successive rounds of directed evolu-
tion using MS-based screening methods. After functional optimiza-
tion of the initial modules an additional module will be added and
the MS-based screening will be adjusted accordingly and so on.
This will eventually result in a pool of compatible initiation, elon-
gation and termination modules that can be assembled in a plug-
and-play fashion using standardized engineering protocols and
an optimized production host for the generation of a desired de
novo constructed product (Fig. 5).
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